<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031211</url>
  </required_header>
  <id_info>
    <org_study_id>29290</org_study_id>
    <nct_id>NCT02031211</nct_id>
  </id_info>
  <brief_title>TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial</brief_title>
  <official_title>Etanercept for the Treatment of Chronic Regional Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic
      Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient
      symptoms if given in early CRPS.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>intrapatient comparisons of Visual Analog Scale on Day 35 vs Visual Analog Scale on Day 1, comparing active drug to placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adolescent Pediatric Pain Tool</measure>
    <time_frame>At end of each week of treatment</time_frame>
    <description>The Adolescent Pediatric Pain Tool is a survey that will be administered at baseline and at the end of each of the four weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Temperature and Volume of Affected Limb</measure>
    <time_frame>At beginning and end of study</time_frame>
    <description>The skin temperature and volume of the affected limb will be measured at the beginning and end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>Beginning and end of study</time_frame>
    <description>The Hospital Anxiety and Depression Scale is a survey that will be administered at the beginning and end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance Scale for Children</measure>
    <time_frame>Beginning and end of the study</time_frame>
    <description>The Sleep Disturbance Scale for Children is a survey that will be administered at the beginning and end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep pattern and quality</measure>
    <time_frame>Daily</time_frame>
    <description>The patient will sleep with a JawboneUp device, which will measure the sleep pattern and quality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>CRPS</condition>
  <condition>Chronic Regional Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.4 ml/kg of normal saline will be administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female pediatric Chronic Regional Pain Syndrome (CRPS) patients with unilateral CRPS
             of the lower extremity, ages 10-17 years of age.

          2. Patients must meet CRPS Type I diagnostic criteria and have current evidence of edema,
             and a temperature difference between the affected and contralateral limb ≥1.0°C.

          3. Duration of symptoms less than 4 months.

        Exclusion Criteria:

          1. Active malignancy or history of malignancy.

          2. Active infection.

          3. History of Tuberculosis (TB) or TB exposure.

          4. Pregnancy.

          5. Concomitant disease causing immunocompromise.

          6. Concomitant autoimmune disease such as rheumatoid arthritis, psoriasis, ankylosing
             spondylitis or Crohn's Disease.

          7. Poorly controlled psychiatric disease including anxiety, depression or attention
             deficit hyperactivity disorder.

          8. Hepatic or renal impairment as indicated by serum transaminases and/or creatinine ≥
             150% normal value for age.

          9. Evidence of or history of demyelinating disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Srinivas Naidu</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

